Kyowa Kirin's bardoxolone program down but not quite out
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin has decided to discontinue a Japanese Phase II clinical trial with bardoxolone methyl for use in chronic kidney disease patients with type 2 diabetes, but has not completely ruled out a new development program in the indication.